Chester County News and Community Website
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced a conference call and webcast to discuss regulatory updates for the nomlabofusp clinical development program for Friedreich’s Ataxia on Monday, …
Larimar Therapeutics to Host Conference Call on Friedreich’s Ataxia Updates Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has unveiled its operational and financial results for the first quarter of 2025, showcasing significant progress in its clinical development program …
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced significant progress in its nomlabofusp program for Friedreich’s Ataxia (FA), reporting key regulatory advancements, ongoing clinical developments, and a robust …
Larimar Therapeutics Advances Nomlabofusp Program Amid Regulatory Support Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced its participation in the upcoming Leerink Partners Global Healthcare Conference, scheduled to take place in Miami Beach, Florida, from …
Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has begun dosing adolescents aged 12-17 in its pediatric pharmacokinetic (PK) run-in study for Friedreich’s ataxia (FA), marking an important step in …
Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced encouraging initial results from its ongoing open-label extension (OLE) study evaluating long-term daily injections of nomlabofusp for Friedreich’s ataxia …
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) recently presented encouraging data from its studies on nomlabofusp at the International Congress for Ataxia Research in London. The data, derived …
Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has released its financial results for the third quarter of 2024, alongside updates on its nomlabofusp program aimed at treating Friedreich’s …
Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced its second-quarter 2024 financial results and significant progress in its nomlabofusp development program.
Larimar Therapeutics Reports Q2 2024 Financial Results and Milestones Read More BALA CYNWYD, PA — Larimar Therapeutics announced that its novel therapy nomlabofusp has been chosen to participate in the FDA’s Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot …
Larimar Therapeutics’ Nomlabofusp Selected for FDA’s START Program Read More